Filing Flows › BioNexus Gene Lab (BGLC) › Q2 2026
BioNexus Gene Lab (BGLC) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 14, 2026
BioNexus Gene Lab (BGLC) reported revenue of $76K for the second quarter 2026 (Q2 2026), -97% from a year earlier and +233% from the quarter before. Operating margin was -370.8%, net loss $286K (376.1% of revenue).
BioNexus Gene Lab, Q2 2026: revenue $76K (-97% year over year), operating margin -370.8%, net loss $286K, operating cash flow −$422K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $76K | +233% | -97% |
| Operating profit | −$282K | — | — |
| Net earnings | −$286K | — | — |
| Operating cash flow | −$422K | — | — |
What changed
Revenue was $76K in Q2 2026, down 97% year over year and up 233% from the previous quarter.
Gross margin was 17.0%, up 0.8 points from Q2 2025. Operating costs exceeded revenue by $282K, an operating margin of -370.8%. Operating expenses fell 70% while revenue fell 97%. The quarter ended with a net loss of $286K, narrower than the previous quarter's $544K loss.
Operating cash flow was −$422K. Non-cash charges added back $28K of depreciation. Working capital and other items used $164K. Capital expenditures of $0K exceeded it, leaving free cash flow of −$423K.
Questions
What was BioNexus Gene Lab's revenue in the second quarter 2026?
BioNexus Gene Lab (BGLC) reported revenue of $76K for the second quarter 2026 (Q2 2026), -97% from a year earlier and +233% from the quarter before.
Was BioNexus Gene Lab profitable in the second quarter 2026?
Operating loss was $282K (-370.8% of revenue) and net loss $286K.
Source: BioNexus Gene Lab 10-Q on SEC EDGAR.